Harmony Biosciences Holdings, Inc. (HRMY)

HRMY Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	181.27	158.69	145.49	128.85	181.47	34.6
Depreciation & Amortization	25.34	25.34	24.11	24.36	23.39	18.84
Other Amortization	0.62	0.65	0.7	2.27	1.66	2.24
Asset Writedown & Restructuring Costs	51.25	34.25	43.6	2.26	-	-
Loss (Gain) From Sale of Investments	-1.26	-1.52	-2.26	-2.72	-0.43	-
Stock-Based Compensation	40.9	44.9	42.6	31.71	26.17	15.66
Other Operating Activities	-1.84	-5.91	-27.1	-2.38	-83.69	26.59
Change in Accounts Receivable	-18.01	-13.75	-8.89	-19.4	-19.9	-12.67
Change in Inventory	-0.26	1.84	-1.84	-1.07	0.14	-0.61
Change in Accounts Payable	-6.62	3.95	-5.38	8.95	2.79	-1.56
Change in Other Net Operating Assets	83.69	99.78	8.79	46.55	12.87	15.46
Operating Cash Flow	355.08	348.2	219.82	219.39	144.47	98.56
Operating Cash Flow Growth	36.90%	58.40%	0.20%	51.86%	46.58%	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-0.18	-0.31	-1.15	-0.31	-0.17	-0.3
Cash Acquisitions	-	-	-33.07	-36.97	-	-
Sale (Purchase) of Intangibles	-51.25	-34.25	-26.5	-	-40	-100
Investment in Securities	-286.14	-5.09	-6.76	-9.16	-101.66	-
Investing Cash Flow	-337.57	-39.65	-67.48	-46.44	-141.83	-100.3

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	-	-	200	-	200
Long-Term Debt Repaid	-	-16.25	-15	-201.25	-2	-200.5
Net Debt Issued (Repaid)	-18.75	-16.25	-15	-1.25	-2	-0.5
Issuance of Common Stock	9.27	10.21	6.5	5.06	8.84	39.37
Repurchase of Common Stock	-4.3	-3	-2.5	-100.51	-	-
Other Financing Activities	-	-	-	-8.84	-	-31.45
Financing Cash Flow	-13.79	-9.05	-11	-105.55	6.84	7.42

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Cash Flow	3.72	299.5	141.34	67.4	9.48	5.68

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	354.9	347.89	218.67	219.08	144.29	98.26
Free Cash Flow Growth	37.17%	59.09%	-0.19%	51.82%	46.85%	-
Free Cash Flow Margin	36.97%	40.06%	30.59%	37.64%	32.95%	32.17%
Free Cash Flow Per Share	6.05	5.94	3.78	3.63	2.36	1.66
Levered Free Cash Flow	182.84	211.46	143.91	214.83	72.97	-123.53
Unlevered Free Cash Flow	190.64	219.97	154.14	227.4	83.05	-110.64

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	13.24	14.69	17.32	20.05	16.36	19.83
Cash Income Tax Paid	5.51	19.82	79.64	48.23	12.65	2.88
Change in Working Capital	58.8	91.82	-7.32	35.04	-4.11	0.63

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error